Arovella Therapeutics Limited

ASX:ALA Stock Report

Mkt Cap: AU$19.6m

We’ve recently updated our valuation analysis.

Arovella Therapeutics Valuation

Is ALA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALA?

Other financial metrics that can be useful for relative valuation.

ALA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue45.6x
Enterprise Value/EBITDA-1.8x
PEG Ration/a

Price to Book Ratio vs Peers

How does ALA's PB Ratio compare to its peers?

The above table shows the PB ratio for ALA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average4.6x
PAA PharmAust
IDT IDT Australia
ILA Island Pharmaceuticals
WFL Wellfully
ALA Arovella Therapeutics

Price-To-Book vs Peers: ALA is good value based on its Price-To-Book Ratio (3.1x) compared to the peer average (4x).

Price to Earnings Ratio vs Industry

How does ALA's PE Ratio compare vs other companies in the AU Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a62.8%

Price-To-Book vs Industry: ALA is expensive based on its Price-To-Book Ratio (3.1x) compared to the Australian Pharmaceuticals industry average (2.6x)

Price to Book Ratio vs Fair Ratio

What is ALA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ALA's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of ALA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALA's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies